NCT07543120
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
Recruiting
PHASE2Ages 18+InterventionalTreatmentNovartis Pharmaceuticals
~323 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:QCZ484
At a glance
Recruiting sites
25 of 25 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with AEs
Measured over Up to 66 months
Conditions
Where it's being run
25 sites across 16 statesFlorida6
Tokyo3
California2
Singapore2
Georgia1
Illinois1
Kansas1
Maryland1
Study leadership
- Novartis Pharmaceuticals · STUDY_DIRECTOR · Novartis Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants with AEsUp to 66 months
Number of participants with Adverse events (AEs), including abnormal safety laboratory parameters and vital signs